Moving from 5mg to 10mg Mounjaro: what the evidence says

What the licensed schedule actually says about dose steps

The Mounjaro Summary of Product Characteristics, held on the electronic Medicines Compendium, sets out the titration ladder precisely: 2.5mg for the first four weeks, then 5mg, 7.5mg, 10mg, 12.5mg, and finally 15mg, with roughly four weeks at each rung. The rationale is tolerability. Tirzepatide slows gastric emptying and acts on appetite centres in the brain, and both effects need time to settle before the dose rises again. Moving from 5mg to 10mg directly would skip 7.5mg and compress two four-week periods into one, which the licensed schedule does not support.

This matters practically because the 7.5mg step is not just a number on a pen. Gastrointestinal side effects, primarily nausea, loose stools and reflux, tend to flare after each increase and then ease over days or a couple of weeks. The stepped approach keeps that window manageable. Skipping it means the body faces a larger adjustment in one go. Some people tolerate this without difficulty; others find it much harder. Neither outcome can be predicted in advance without a clinical conversation.

If you feel 5mg has stopped working (you can read more about appetite suppression stalling at lower doses) the right route is a review with your prescriber, not a unilateral step up. They will look at how long you have been on 5mg, your current weight trajectory, and whether any side effects are still present.

Why going backwards (from 10mg to 5mg) is also a real clinical decision

The flip side of this question comes up often in practice. Some people reach 10mg and find the side effects harder than they expected. Going back from 10mg to 5mg is also a prescriber-led decision. There is no clinical shame in it. The dose escalation pathway in the Mounjaro SmPC is described as a guide to tolerability, not a race. A prescriber may move someone down temporarily and then try the higher dose again once the system has settled.

The SURMOUNT-1 trial, published in the New England Journal of Medicine, showed that across more than 2,500 adults the higher maintenance doses produced greater average weight loss over 72 weeks, with the 15mg group reaching around 20–21% average body-weight reduction. But the trial also maintained the incremental schedule throughout. Participants were not escalated faster because they wanted a quicker result. The structure was baked into the protocol precisely because rapid escalation increases the likelihood of stopping due to side effects.

If you are weighing up a dose reduction, the page on stepping down from 15mg to 10mg covers the same principles in detail. The clinical logic is the same at any point in the ladder.

What a prescriber actually looks at before approving a dose change

Before any change (up or down) a prescriber will want to know several things. How long have you been at the current dose? Four weeks is the minimum the schedule allows, and for some people the prescriber may want longer if side effects are still settling. Have you lost weight during this period? Consistent loss, even modest, is a signal the current dose is doing something useful. Are you experiencing ongoing nausea, vomiting or other GI effects that a higher dose would likely amplify?

At nume, every repeat order goes through a fresh clinical review by a GPhC-registered prescriber before anything is dispensed. That includes dose changes. There is no automated process that simply ticks a box and moves you up. The prescriber reads your answers, checks your reported weight, and makes a clinical judgement. If 7.5mg was tolerated well and you have been at 5mg for at least four weeks with stable or improving response, a move to 7.5mg (not 10mg) would typically be the next step under the licensed schedule.

For context on cost at higher doses, the Eli Lilly price increase for UK Mounjaro pens is worth understanding before you plan your titration; higher-strength pens carry a higher list price since the September 2025 changes. Full pricing for the treatment is shown on our treatment and consultation page.

What to do if you think your dose needs to change

If you are currently at 5mg and wondering whether 10mg is your next move, the honest answer is: it depends, and that dependency is exactly what the clinical review is for. You may be ready for 7.5mg. You may benefit from another few weeks at 5mg. In rare cases there are clinical reasons to consider a non-standard step, but those decisions belong with the prescriber, not a search result.

It is completely understandable to feel impatient at 5mg, especially if you have been reading about the results achieved at higher doses. The gap between where you are and where you want to be can feel frustrating. The titration schedule is not a delay tactic; it is the method by which those results were actually achieved in the trials.

The NHS medicines page for tirzepatide gives a plain-language overview of the treatment and its schedule, and the Patient Information Leaflet inside your pen's packaging covers your specific product. Both are worth reading alongside your prescriber's guidance. For questions about earlier steps in the titration, the pages on jumping from 2.5mg to 7.5mg and reducing back to 2.5mg cover similar ground at different points on the ladder, and if you are using a higher-strength pen and wondering about your options, our guide on whether you can dose 5mg from a 7.5mg Mounjaro pen explains what is and is not possible.

If you'd like a prescriber to look at your current dose and next step properly, speak to our prescribers through a free consultation and they'll review your full picture the same day.